Found: 1
Select item for more details and to access through your institution.
Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 300, doi. 10.1007/s10637-021-01180-9
- By:
- Publication type:
- Article